Waaree Energies — a commodity earning branded margins, on a policy lease

The Pulse

Waaree Energies makes solar panels, and for the last two years it has been one of the most spectacular profit stories in Indian manufacturing — a maker of what is fundamentally a commodity, earning the margins of a branded business. Revenue in FY26 grew 84% to ₹26,537 crore and net profit doubled to ₹3,884 crore, on operating margins that have re-rated from a wafer-thin 4–5% a few years ago to 22%, with return on capital around 32–39%. The engine behind this is not really the panel; it is access. Waaree is the world’s largest non-Chinese module maker, which lets it sell into the United States — where trade walls have shut China out — at prices nearly double those at home, topped up by American manufacturing subsidies. That single fact powers most of the profitability. The company is now ploughing those profits, plus a planned ₹10,000 crore equity raise, into a ~₹30,000 crore expansion (“Waaree 2.0”) that pushes backward into cells, wafers and even polysilicon and outward into batteries, inverters and electrolysers. The two questions that decide everything are visible in the latest results: how durable are these fat margins (the March quarter showed they’re cyclical — silver prices, Red Sea freight and a sales-mix shift knocked nearly six percentage points off in one quarter), and how much of the profit pool is on lease from US trade policy that an election could rewrite.

The Business — scale, and the right passport

Strip it down and Waaree manufactures solar photovoltaic modules — the panels on rooftops and in solar farms — and increasingly the cells inside them. It is India’s largest, with roughly 18–21 GW of module capacity (about 16 GW in India and a growing US base) and ~5.4 GW of cell capacity. It earns money two ways with very different economics: selling at home, where panels fetch around 16–17 US cents a watt, and exporting — chiefly to the US — where they fetch 26–30 cents. That export gap is the whole game. Exports run roughly half the order book, and the US slice carries both premium pricing and a manufacturing tax credit worth about 7 cents a watt.

The honest framing of the moat matters here, because a solar module is, at bottom, a commodity — China makes it cheapest, and on a level playing field would win. Waaree’s advantage is therefore not the product but a stack of barriers around it: it is non-Chinese at scale, which is precisely what US rules (tariffs, the “FEOC” ban on Chinese-linked suppliers from April 2026, forced-labour import bans) and Indian rules (the ALMM approved-list regime that protects domestic cells from 2026 and wafers from 2028) are built to reward. Add genuine scale, an established brand with the “bankability” that lets financiers underwrite its panels, a wide franchisee distribution network at home, and an emerging push into making its own cells and wafers, and you have a strong, defensible position. But it is a position granted by policy — a regulatory moat rented from Washington and Delhi, not an intrinsic one. The promoter, Dr. Hitesh Doshi, has run the group since 1990 and holds ~64%; a professional CEO was brought in shortly after the October 2024 IPO.

How Management Thinks — ambitious, integration-obsessed, mostly candid

This is a management team in full land-grab mode, and it talks like one — confident, platform-minded, fond of framing the addressable market as expanding from a trillion to four trillion dollars. The capital-allocation philosophy is unambiguous: reinvest everything. Dividends have been essentially nil since well before listing (a token ₹2 interim is the first gesture), and instead the company is committing ~~₹30,000 crore (~~$3.5 billion) of capex across some ten verticals over the next couple of years, funded by operating cash, debt headroom and a fresh ₹10,000 crore equity raise. The logic is “build the integrated platform now, while the window is open” — backward into cells, ingots, wafers and non-Chinese polysilicon (a plant in Oman, prized because its output is traceable as China-free for the US market), and outward into battery storage, inverters, electrolysers for green hydrogen, transformers, and even owning solar power plants.

On candour, the read is mixed but mostly favourable. Management is genuinely forthcoming on the hard operating numbers — volumes, average selling prices, the cost structure down to silver’s share of a cell — and it beat its own FY26 profit “North Star,” delivering ₹6,617 crore of reported EBITDA against guidance of ₹5,500–6,000 crore. It also proactively booked a ₹294 crore provision against a US investigation into whether it used Chinese cells in the past — owning an awkward issue before being forced to. The deflections are equally telling: it dodged specifics on anti-dumping liabilities, was slow to give forward guidance, never cleanly reconciled two different EBITDA figures it quoted in the same call, and got pressed by analysts on cell-plant utilisation that looked weak on the face of it. There have even been small disclosure slips a sharp investor caught on a call (a sign error in a cash-flow line the CFO conceded) — the kind of rough edge you expect from a company barely a year into public life. The boldest claim to file away and check is the promise of 19–20% margins sustained “for a decade” — an extraordinary thing to underwrite for a product the rest of the world treats as a commodity.

Where It’s Going — more capacity, bigger bets, the same policy dependence

The forward plan is growth stacked on growth. Management guides FY27 operating EBITDA to ₹7,000–7,700 crore, and the central margin lever is backward integration: roughly tripling cell capacity from 5.4 GW toward 15.4 GW so that Waaree stops buying third-party cells (which diluted margins in the weak March quarter) and captures that economics itself. US capacity is set to expand from 1.6 to 4.2 GW within months to feed the premium market directly. The bull case is real and large: US solar demand is booming on the back of AI data-centre power needs (the country is heading from ~50 toward 70–80 GW a year), the FEOC rules tighten the screws on China further, and India’s ALMM regime hands domestic players a protected runway.

The tensions are just as real. The March quarter was a useful cold shower — margins fell almost six points in three months on a silver-and-copper cost spike, Red Sea shipping chaos that stranded export inventory, and a mix that tilted away from high-price overseas sales; the order book also slipped about ₹7,000 crore to ₹53,000 crore as some overseas deliveries deferred and a domestic policy freeze bit. Working capital has stretched (receivable-plus-inventory days roughly doubling toward 90), free cash flow is deeply negative as the capex lands, and the entire premium profit pool sits downstream of US policy that has already produced one scare (a preliminary 126% countervailing duty on Indian cells, which Waaree argues doesn’t touch it because it doesn’t use Indian cells for US supply) and could change with the next administration. The diversification into ten verticals is genuine optionality but also a real risk of spreading the organisation thin into businesses — batteries, electrolysers, semiconductors — where Waaree has no track record yet. In short: a company executing well and growing explosively, riding a protected window for all it’s worth, while pouring enormous capital into widening the platform before the window’s terms can change.

The Four Checks

Quality & moat (gate). A solar module is a commodity; the moat is not the product but a policy-granted position — being the largest non-Chinese maker exactly when the US and India are legislating China out of their markets, reinforced by scale, brand/bankability, and emerging integration. That is a strong, profitable position, but a rented one: it exists because of trade barriers, and it erodes if China regains access, if Southeast-Asian or other Indian players scale up the non-Chinese supply, or if subsidies lapse. Real moat, finite lease — judge everything below through that lens.
Returns on incremental capital & runway. Current returns are exceptional (ROCE ~32–39%, once as high as ~52%) and the runway is enormous in raw size — a vast capex programme into a large, growing market. The catch is the quality of incremental returns: the new capacity is being built at peak-cycle margins, and the March quarter is direct evidence those margins are cyclical and policy-sensitive. So the honest read is high current returns and a long runway, but genuine uncertainty about what the ₹30,000 crore now being deployed will actually earn through a cycle — possibly well below today’s headline ROCE.
Capital allocation for the stage. Reinvesting everything and paying no dividend is correct behaviour while returns on capital are this high — textbook for the stage. Two caveats temper the grade: it is reinvesting aggressively (and raising ₹10,000 crore of fresh equity) into a commodity at what may be peak margins, and it is fanning out into ~10 verticals where execution is unproven — a real risk of diworsification. Directionally rational, but the breadth and the timing carry the risk. No buyback, which is appropriate — the stock isn’t cheap and the business genuinely needs the capital.
Price. At ~22x earnings the multiple looks undemanding for ~doubling profits — but only if you believe the margins hold. Those earnings sit on peak-cycle, policy-boosted margins; capitalise a normalised 19–20% (or lower) margin and the picture is richer, and the ~6x book value already prices in a lot of the integration paying off. Market cap is ~₹87,000 crore. The price is effectively a bet that the US policy window stays open and the capex executes flawlessly — fair if both hold, demanding on a through-cycle view if either wobbles. Reasoned characterisation, not a recommendation.

Sources

Concall transcripts read: Q2 FY26 (17 Oct 2025), Q3 FY26 (Jan 2026), a special clarification call on the US 126% countervailing duty (25 Feb 2026, no fresh financials), and Q4/FY26 (30 Apr 2026). Promoter/CMD Hitesh Doshi, CEO and CFO on the results calls.
Annual report read: FY25 only — Waaree’s first as a listed company (IPO October 2024), so there is no multi-year annual-report history yet; trimmed high-signal sections.
Snapshot: screener.in consolidated, fetched 2026-06-09 (logged-out). Current figures cited (FY26 revenue ₹26,537 cr, PAT ₹3,884 cr, OPM 22%, ROCE ~33–39%, P/E ~22, P/B ~6x, market cap ~₹87,000 cr, ~0% payout, promoter ~64%) are from this snapshot.
Gaps flagged: the April-2026 quarter had a presentation only (no transcript) and was skipped; the Feb-2026 call was a policy-clarification event, not a results quarter; the FY25 annual-report extraction was fragmented (the chairman’s full letter, the detailed China/ALMM risk table, and the IPO use-of-proceeds reconciliation did not survive trimming), so moat/risk language there is lighter than the concalls. Two minor disclosure slips (an unreconciled EBITDA figure, a cash-flow sign error) were noted in the underlying digests.
Full research dumps: vault/Sources/Earnings/Waaree Energies Ltd/ (not published).